Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2015. Refer to TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | ledipasvir / sofosbuvir (Harvoni®) | ||
| Formulation | 90 mg/400 mg film-coated tablet | ||
| Reference number | 1887 | ||
| Indication | Treatment of chronic hepatitis C in adults |
||
| Company | Gilead Sciences Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 0915 | ||
| NMG meeting date | 18/03/2015 | ||
| AWMSG meeting date | 22/04/2015 | ||
| Ratification by Welsh Government | 12/08/2015 | ||
| Date of issue | 12/08/2015 | ||
| NICE guidance | TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
||